U.S. markets open in 5 hours 10 minutes
  • S&P Futures

    4,231.25
    +21.50 (+0.51%)
     
  • Dow Futures

    33,457.00
    +153.00 (+0.46%)
     
  • Nasdaq Futures

    13,382.50
    +71.25 (+0.54%)
     
  • Russell 2000 Futures

    1,989.40
    +13.10 (+0.66%)
     
  • Crude Oil

    94.41
    +0.07 (+0.07%)
     
  • Gold

    1,804.50
    -2.70 (-0.15%)
     
  • Silver

    20.33
    -0.01 (-0.07%)
     
  • EUR/USD

    1.0294
    -0.0031 (-0.30%)
     
  • 10-Yr Bond

    2.8880
    0.0000 (0.00%)
     
  • Vix

    20.15
    +0.41 (+2.08%)
     
  • GBP/USD

    1.2170
    -0.0032 (-0.26%)
     
  • USD/JPY

    133.2670
    +0.2680 (+0.20%)
     
  • BTC-USD

    23,992.69
    -432.65 (-1.77%)
     
  • CMC Crypto 200

    569.97
    -4.77 (-0.83%)
     
  • FTSE 100

    7,501.94
    +36.03 (+0.48%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

Don't be duped by doomsayers, JPMorgan says — the S&P 500 will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce

·3 min read
Don't be duped by doomsayers, JPMorgan says — the S&P 500 will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce
Don't be duped by doomsayers, JPMorgan says — the S&P 500 will rebound to 4,900. Here are 3 stocks it's using to bet on a bounce

Looking at the S&P 500 right now, you might be convinced the stock market is destined for doom in 2022.

The benchmark index rose nearly 27% last year. This year, it’s already down 20%. Plenty of stocks are deep into correction territory.

Yet JPMorgan’s global head of equity macro research, Dubravko Lakos, sees a major rebound on the horizon.

“People are basically positioned for a recession. Our base case is that this is not going to be a recession in the next 12 months,” Lakos told CNBC last month. “And we think from that angle the portfolios are wrong footed.”

Lakos reiterated a year-end price target of 4,900 for the S&P 500. Since the index sits at 3,820 today, his target implies a potential upside of around 28%.

If you’re aligned with Lakos and are looking ahead to a potential reversal, here’s three stocks JPMorgan finds particularly attractive right now.

Don’t miss

Smartsheet (SMAR)

This work-management platform helps companies implement, organize and automate their processes. Smartsheet says its application is used by more than 80% of Fortune 500 companies.

And business is growing. In the fiscal quarter ended April 30, revenue surged 44% year over year to $168.3 million, driven by a 44% increase in subscription revenue.

Notably, Smartsheet’s dollar-based net retention rate was a solid 133%.

But the stock is far from being a hot commodity. Year to date, shares are down a painful 55%. That could give contrarian investors something to think about.

Last month, JPMorgan analyst Pinjalim Bora reiterated an “overweight” rating on Smartsheet. While Bora also lowered his price target from $80 to $58, the new target is still 69% above where the stock sits today.

Microsoft (MSFT)

Tech stocks are getting dumped in this market downturn. Even mega-cap behemoths like Microsoft aren’t immune to the bearish sentiment.

The stock has tumbled 22% in 2022.

But business remains on the right track. In the March quarter, Microsoft’s revenue grew 18% year over year to $49.4 billion. Adjusted earnings came in at $2.22 per share, up 9% from the year-ago period.

The tech gorilla is also returning a massive amount of cash to investors. For the quarter, Microsoft’s dividends and share buybacks totaled $12.4 billion, representing a 25% increase year over year.

JPMorgan analyst Mark Murphy recently raised his price target on Microsoft to $320 while maintaining a “buy” rating. That implies a potential upside of 22%.

Eli Lilly (LLY)

This American pharmaceutical giant commands more than $300 billion in market cap, with products marketed in 120 countries around the world.

Unlike the other two names on this list, Eli Lilly is not a beaten-down stock.

In Q1, Eli Lilly delivered 15% revenue growth, driven by a 20% growth in volume. The company paid nearly $900 million in dividends and spent $1.5 billion on buybacks during the quarter.

Shares are actually up 19% so far in 2022, and JPMorgan expects the trend to continue.

On June 1, analyst Chris Schott reiterated an “overweight” rating on Eli Lilly while raising his price target from $340 to $355.

Considering that shares trade at around $325 apiece right now, the new price target implies a potential upside of 9%.

What to read next

This article provides information only and should not be construed as advice. It is provided without warranty of any kind.